Abstract: Mesofluidic devices for culturing cell aggregates and methods of using the same are disclosed. An exemplary mesofluidic device comprises at least one fluid inlet, at least one fluid outlet, a plurality of fluid channels, and a plurality of culture chambers. Each culture chamber can comprise at least one chamber inlet and at least one chamber outlet. The at least one chamber inlet can be in fluid communication with the at least one fluid inlet via at least one of the plurality of fluid channels. The at least one chamber outlet can be in fluid communication with the at least one fluid outlet via at least one of the plurality of fluid channels. The mesofluidic device can be configured to contain a cell aggregate in each of the plurality of culture chambers.

Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: Mesofluidic devices for culturing cell aggregates and methods of using the same are disclosed. An exemplary mesofluidic device comprises at least one fluid inlet, at least one fluid outlet, a plurality of fluid channels, and a plurality of culture chambers. Each culture chamber can comprise at least one chamber inlet and at least one chamber outlet. The at least one chamber inlet can be in fluid communication with the at least one fluid inlet via at least one of the plurality of fluid channels. The at least one chamber outlet can be in fluid communication with the at least one fluid outlet via at least one of the plurality of fluid channels The mesofluidic device can be configured to contain a cell aggregate in each of the plurality of culture chambers.

Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.